منابع مشابه
Risk calculation for hyperkalaemia in heart failure patients.
BACKGROUND We aimed to develop a model to estimate the risk of hyperkalaemia in patients treated for heart failure in a tertiary reference hospital and to identify precipitating factors. METHODS 125 congestive heart failure (CHF) patients were studied retrospectively. Thirty of these patients developed episodes of hyperkalaemia (K>or=5.5 mmol/l). Both groups were compared for possible risk fa...
متن کاملResponse to: Hyperkalaemia in heart failure: binding the patient to improved treatment?
We appreciate the insightful and balanced Editorial1 by Dr Konstam regarding our study.2 However, we wish to take issue with one of his statements and its implications. The Editorial states, “Over 4 weeks, in each trial, patients were allowed to have serum potassium levels as high as 6.2mmol/L (HARMONIZE) or 6.5mmol/L (OPAL-HK) without intervention and, apparently, they tolerated these levels w...
متن کاملHyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study.
1 Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: population-based study. BMJ 1998;316:1343-7. 2 Basso O, Olsen J, Christensen K. Recurrence risk of congenital anomalies—the impact of paternal, social, and environmental factors: a population-based study in Denmark. Am J Epidemiol 1999;150:598-604. 3 Li DK. Changi...
متن کاملHyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone.
BACKGROUND Recent studies have shown a fall in global mortality with minimal side effects in severe congestive heart failure (CHF) patients receiving angiotensin-converting enzyme inhibitors (ACEI) plus spironolactone (SLN). However, the risk of hyperkalaemia due to ACEI may be increased by the concomitant use of SLN. METHODS We conducted a retrospective cohort study by examining consecutive ...
متن کاملAcute renal failure and hyperkalaemia associated with cyclooxygenase-2 inhibitors.
BACKGROUND The renal effects of cyclooxygenase-2 (COX-2) inhibitors have been incompletely elucidated, and acute renal failure (ARF) due to COX-2 inhibitors has been reported. METHODS In order to determine the causes of ARF and hyperkalaemia in five patients during COX-2 inhibitor therapy, we carefully analysed case studies of consecutive in-patients or out-patients referred to our Renal Divi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cardiac Failure Review
سال: 2021
ISSN: 2057-7559,2057-7540
DOI: 10.15420/cfr.2020.29